Tiziana Signs MOU to Test Foralumab Combo in RRMS
TLSA is trading near its 52-week low of $0.762 (7.3% above the low).
Summary
Tiziana Life Sciences signed an MOU with KAIMRC and the Foundation for Neurologic Diseases to study intranasal foralumab combined with anti-CD20 therapy in RRMS patients who respond poorly to anti-CD20 alone. This expands foralumab's pipeline beyond na-SPMS into a defined clinical niche with unmet need. The company's na-SPMS Phase 2 readout remains expected in October, a near-term binary event. Prior studies showed neuroinflammation reduction, supporting the combination rationale. A formal trial initiation and positive efficacy signals would broaden the drug's addressable market and could attract partnerships or funding.
At the time of this announcement, TLSA was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98.8M. The 52-week trading range was $0.76 to $2.35. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.